Bangladesh · Delayed Price · Currency is BDT DSE:SQURPHARMA Statistics
Total Valuation
DSE:SQURPHARMA has a market cap or net worth of BDT 194.84 billion. The enterprise value is 124.89 billion.
| Market Cap | 194.84B |
| Enterprise Value | 124.89B |
Important Dates
The last earnings date was Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Nov 17, 2025 |
Share Statistics
DSE:SQURPHARMA has 886.45 million shares outstanding.
| Current Share Class | 886.45M |
| Shares Outstanding | 886.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 44.10% |
| Owned by Institutions (%) | 4.00% |
| Float | 495.49M |
Valuation Ratios
The trailing PE ratio is 7.51 and the forward PE ratio is 6.81.
| PE Ratio | 7.51 |
| Forward PE | 6.81 |
| PS Ratio | 2.38 |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | 12.96 |
| P/OCF Ratio | 9.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.64, with an EV/FCF ratio of 8.31.
| EV / Earnings | 4.81 |
| EV / Sales | 1.52 |
| EV / EBITDA | 4.64 |
| EV / EBIT | 5.05 |
| EV / FCF | 8.31 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.73 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.03 |
| Interest Coverage | 149.24 |
Financial Efficiency
Return on equity (ROE) is 19.01% and return on invested capital (ROIC) is 20.41%.
| Return on Equity (ROE) | 19.01% |
| Return on Assets (ROA) | 8.84% |
| Return on Invested Capital (ROIC) | 20.41% |
| Return on Capital Employed (ROCE) | 14.99% |
| Weighted Average Cost of Capital (WACC) | 4.59% |
| Revenue Per Employee | 5.14M |
| Profits Per Employee | 1.63M |
| Employee Count | 15,937 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 3.08 |
Taxes
In the past 12 months, DSE:SQURPHARMA has paid 5.53 billion in taxes.
| Income Tax | 5.53B |
| Effective Tax Rate | 17.55% |
Stock Price Statistics
The stock price has increased by +1.10% in the last 52 weeks. The beta is 0.05, so DSE:SQURPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | +1.10% |
| 50-Day Moving Average | 206.52 |
| 200-Day Moving Average | 212.45 |
| Relative Strength Index (RSI) | 73.59 |
| Average Volume (20 Days) | 716,349 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:SQURPHARMA had revenue of BDT 81.95 billion and earned 25.95 billion in profits. Earnings per share was 29.27.
| Revenue | 81.95B |
| Gross Profit | 39.60B |
| Operating Income | 21.74B |
| Pretax Income | 31.48B |
| Net Income | 25.95B |
| EBITDA | 23.94B |
| EBIT | 21.74B |
| Earnings Per Share (EPS) | 29.27 |
Balance Sheet
The company has 59.67 billion in cash and 512.49 million in debt, with a net cash position of 69.96 billion or 78.92 per share.
| Cash & Cash Equivalents | 59.67B |
| Total Debt | 512.49M |
| Net Cash | 69.96B |
| Net Cash Per Share | 78.92 |
| Equity (Book Value) | 143.97B |
| Book Value Per Share | 162.40 |
| Working Capital | 62.75B |
Cash Flow
In the last 12 months, operating cash flow was 21.63 billion and capital expenditures -6.60 billion, giving a free cash flow of 15.03 billion.
| Operating Cash Flow | 21.63B |
| Capital Expenditures | -6.60B |
| Free Cash Flow | 15.03B |
| FCF Per Share | 16.96 |
Margins
Gross margin is 48.32%, with operating and profit margins of 26.53% and 31.66%.
| Gross Margin | 48.32% |
| Operating Margin | 26.53% |
| Pretax Margin | 38.41% |
| Profit Margin | 31.66% |
| EBITDA Margin | 29.21% |
| EBIT Margin | 26.53% |
| FCF Margin | 18.34% |
Dividends & Yields
This stock pays an annual dividend of 12.00, which amounts to a dividend yield of 5.46%.
| Dividend Per Share | 12.00 |
| Dividend Yield | 5.46% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 8 |
| Payout Ratio | 37.44% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.46% |
| Earnings Yield | 13.32% |
| FCF Yield | 7.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 23, 2020 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
DSE:SQURPHARMA has an Altman Z-Score of 8.95 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.95 |
| Piotroski F-Score | 5 |